Tuesday, October 10, 2017


TTNP Titan Pharmaceuticals, Inc. gains 18% Oct 10, 2017

Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases, such as Parkinson's disease. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment. It is also developing ProNeura-Ropinirole, an implant to provide long-term delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; ProNeura-Triiodothyronine, an implant to provide long-term delivery of triiodothyronine for the treatment of hypothyroidism; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive